Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1997 Aug;71(8):5774–5781. doi: 10.1128/jvi.71.8.5774-5781.1997

Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

M Kotler 1, M Simm 1, Y S Zhao 1, P Sova 1, W Chao 1, S F Ohnona 1, R Roller 1, C Krachmarov 1, M J Potash 1, D J Volsky 1
PMCID: PMC191831  PMID: 9223465

Abstract

Human immunodeficiency virus type 1 (HIV-1) Vif is required for productive infection of T lymphocytes and macrophages. Virions produced in the absence of Vif have abnormal core morphology and those produced in primary T cells carry immature core proteins and low levels of mature capsid (M. Simm, M. Shahabuddin, W. Chao, J. S. Allan, and D. J. Volsky, J. Virol. 69:4582-4586, 1995). To investigate whether Vif influences the activity of HIV-1 protease (PR), the viral enzyme which is responsible for processing Gag and Gag-Pol precursor polyproteins into mature virion components, we transformed bacteria to inducibly express truncated Gag-Pol fusion proteins and Vif. We examined the cleavage of polyproteins consisting of matrix to PR (Gag-PR), capsid to PR (CA-PR), and p6Pol to PR (p6Pol-PR) and evaluated HIV-1 protein processing at specific sites by Western blotting using antibodies against matrix, capsid, and PR proteins. We found that Vif modulates HIV-1 PR activity in bacteria mainly by preventing the release of mature MA and CA from Gag-PR, CA from CA-PR, and p6Pol from p6Pol-PR, with other cleavages being less affected. Using subconstructs of Vif, we mapped this activity to the N-terminal half of the molecule, thus identifying a new functional domain of Vif. Kinetic study of p6Pol-PR autocatalysis in the presence or absence of Vif revealed that Vif and N'Vif reduce the rate of PR-mediated proteolysis of this substrate. In an assay of in vitro proteolysis of a synthetic peptide substrate by purified recombinant PR we found that recombinant Vif and the N-terminal half of the molecule specifically inhibit PR activity at a molar ratio of the N-terminal half of Vif to PR of about 1. These results suggest a mechanism and site of action of Vif in HIV-1 replication and demonstrate novel regulation of a lentivirus PR by an autologous viral protein acting in trans.

Full Text

The Full Text of this article is available as a PDF (1,013.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldrovandi G. M., Zack J. A. Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice. J Virol. 1996 Mar;70(3):1505–1511. doi: 10.1128/jvi.70.3.1505-1511.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Almog N., Roller R., Arad G., Passi-Even L., Wainberg M. A., Kotler M. A p6Pol-protease fusion protein is present in mature particles of human immunodeficiency virus type 1. J Virol. 1996 Oct;70(10):7228–7232. doi: 10.1128/jvi.70.10.7228-7232.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arrigo S. J., Huffman K. Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers. J Virol. 1995 Oct;69(10):5988–5994. doi: 10.1128/jvi.69.10.5988-5994.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Borman A. M., Quillent C., Charneau P., Dauguet C., Clavel F. Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol. 1995 Apr;69(4):2058–2067. doi: 10.1128/jvi.69.4.2058-2067.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Camaur D., Trono D. Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol. 1996 Sep;70(9):6106–6111. doi: 10.1128/jvi.70.9.6106-6111.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Casareale D., Stevenson M., Sakai K., Volsky D. J. A human T-cell line resistant to cytopathic effects of the human immunodeficiency virus (HIV). Virology. 1987 Jan;156(1):40–49. doi: 10.1016/0042-6822(87)90434-x. [DOI] [PubMed] [Google Scholar]
  7. Chowdhury I. H., Chao W., Potash M. J., Sova P., Gendelman H. E., Volsky D. J. vif-negative human immunodeficiency virus type 1 persistently replicates in primary macrophages, producing attenuated progeny virus. J Virol. 1996 Aug;70(8):5336–5345. doi: 10.1128/jvi.70.8.5336-5345.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Courcoul M., Patience C., Rey F., Blanc D., Harmache A., Sire J., Vigne R., Spire B. Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J Virol. 1995 Apr;69(4):2068–2074. doi: 10.1128/jvi.69.4.2068-2074.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cullen B. R. Regulation of human immunodeficiency virus replication. Annu Rev Microbiol. 1991;45:219–250. doi: 10.1146/annurev.mi.45.100191.001251. [DOI] [PubMed] [Google Scholar]
  10. Dougherty W. G., Semler B. L. Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes. Microbiol Rev. 1993 Dec;57(4):781–822. doi: 10.1128/mr.57.4.781-822.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fisher A. G., Ensoli B., Ivanoff L., Chamberlain M., Petteway S., Ratner L., Gallo R. C., Wong-Staal F. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science. 1987 Aug 21;237(4817):888–893. doi: 10.1126/science.3497453. [DOI] [PubMed] [Google Scholar]
  12. Fouchier R. A., Simon J. H., Jaffe A. B., Malim M. H. Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol. 1996 Dec;70(12):8263–8269. doi: 10.1128/jvi.70.12.8263-8269.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gabuzda D. H., Lawrence K., Langhoff E., Terwilliger E., Dorfman T., Haseltine W. A., Sodroski J. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol. 1992 Nov;66(11):6489–6495. doi: 10.1128/jvi.66.11.6489-6495.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gabuzda D. H., Li H., Lawrence K., Vasir B. S., Crawford K., Langhoff E. Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages. J Acquir Immune Defic Syndr. 1994 Sep;7(9):908–915. [PubMed] [Google Scholar]
  15. Garrett E. D., Tiley L. S., Cullen B. R. Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products. J Virol. 1991 Mar;65(3):1653–1657. doi: 10.1128/jvi.65.3.1653-1657.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Goncalves J., Jallepalli P., Gabuzda D. H. Subcellular localization of the Vif protein of human immunodeficiency virus type 1. J Virol. 1994 Feb;68(2):704–712. doi: 10.1128/jvi.68.2.704-712.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Goobar-Larsson L., Luukkonen B. G., Unge T., Schwartz S., Utter G., Strandberg B., Oberg B. Enhancement of HIV-1 proteinase activity by HIV-1 reverse transcriptase. Virology. 1995 Jan 10;206(1):387–394. doi: 10.1016/s0042-6822(95)80054-9. [DOI] [PubMed] [Google Scholar]
  18. Höglund S., Ohagen A., Lawrence K., Gabuzda D. Role of vif during packing of the core of HIV-1. Virology. 1994 Jun;201(2):349–355. doi: 10.1006/viro.1994.1300. [DOI] [PubMed] [Google Scholar]
  19. Kan N. C., Franchini G., Wong-Staal F., DuBois G. C., Robey W. G., Lautenberger J. A., Papas T. S. Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera. Science. 1986 Mar 28;231(4745):1553–1555. doi: 10.1126/science.3006245. [DOI] [PubMed] [Google Scholar]
  20. Kaplan A. H., Manchester M., Swanstrom R. The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J Virol. 1994 Oct;68(10):6782–6786. doi: 10.1128/jvi.68.10.6782-6786.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kaplan A. H., Swanstrom R. Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4528–4532. doi: 10.1073/pnas.88.10.4528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Karacostas V., Wolffe E. J., Nagashima K., Gonda M. A., Moss B. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology. 1993 Apr;193(2):661–671. doi: 10.1006/viro.1993.1174. [DOI] [PubMed] [Google Scholar]
  23. Kotler M., Arad G., Hughes S. H. Human immunodeficiency virus type 1 gag-protease fusion proteins are enzymatically active. J Virol. 1992 Nov;66(11):6781–6783. doi: 10.1128/jvi.66.11.6781-6783.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kräusslich H. G. Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3213–3217. doi: 10.1073/pnas.88.8.3213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kräusslich H. G., Ochsenbauer C., Traenckner A. M., Mergener K., Fäcke M., Gelderblom H. R., Bosch V. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology. 1993 Feb;192(2):605–617. doi: 10.1006/viro.1993.1077. [DOI] [PubMed] [Google Scholar]
  26. Lee T. H., Coligan J. E., Allan J. S., McLane M. F., Groopman J. E., Essex M. A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science. 1986 Mar 28;231(4745):1546–1549. doi: 10.1126/science.3006243. [DOI] [PubMed] [Google Scholar]
  27. Liu H., Wu X., Newman M., Shaw G. M., Hahn B. H., Kappes J. C. The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J Virol. 1995 Dec;69(12):7630–7638. doi: 10.1128/jvi.69.12.7630-7638.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Louis J. M., McDonald R. A., Nashed N. T., Wondrak E. M., Jerina D. M., Oroszlan S., Mora P. T. Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli. Eur J Biochem. 1991 Jul 15;199(2):361–369. doi: 10.1111/j.1432-1033.1991.tb16132.x. [DOI] [PubMed] [Google Scholar]
  29. Luukkonen B. G., Fenyö E. M., Schwartz S. Overexpression of human immunodeficiency virus type 1 protease increases intracellular cleavage of Gag and reduces virus infectivity. Virology. 1995 Feb 1;206(2):854–865. doi: 10.1006/viro.1995.1008. [DOI] [PubMed] [Google Scholar]
  30. Ma X. Y., Sova P., Chao W., Volsky D. J. Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity. J Virol. 1994 Mar;68(3):1714–1720. doi: 10.1128/jvi.68.3.1714-1720.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Michaels F. H., Hattori N., Gallo R. C., Franchini G. The human immunodeficiency virus type 1 (HIV-1) vif protein is located in the cytoplasm of infected cells and its effect on viral replication is equivalent in HIV-2. AIDS Res Hum Retroviruses. 1993 Oct;9(10):1025–1030. doi: 10.1089/aid.1993.9.1025. [DOI] [PubMed] [Google Scholar]
  32. Oberste M. S., Gonda M. A. Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes. 1992 Jan;6(1):95–102. doi: 10.1007/BF01703760. [DOI] [PubMed] [Google Scholar]
  33. Pettit S. C., Moody M. D., Wehbie R. S., Kaplan A. H., Nantermet P. V., Klein C. A., Swanstrom R. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol. 1994 Dec;68(12):8017–8027. doi: 10.1128/jvi.68.12.8017-8027.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Quillent C., Borman A. M., Paulous S., Dauguet C., Clavel F. Extensive regions of pol are required for efficient human immunodeficiency virus polyprotein processing and particle maturation. Virology. 1996 May 1;219(1):29–36. doi: 10.1006/viro.1996.0219. [DOI] [PubMed] [Google Scholar]
  35. Rhim H., Echetebu C. O., Herrmann C. H., Rice A. P. Wild-type and mutant HIV-1 and HIV-2 Tat proteins expressed in Escherichia coli as fusions with glutathione S-transferase. J Acquir Immune Defic Syndr. 1994 Nov;7(11):1116–1121. [PubMed] [Google Scholar]
  36. Roberts N. A., Martin J. A., Kinchington D., Broadhurst A. V., Craig J. C., Duncan I. B., Galpin S. A., Handa B. K., Kay J., Kröhn A. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990 Apr 20;248(4953):358–361. doi: 10.1126/science.2183354. [DOI] [PubMed] [Google Scholar]
  37. Sakai H., Shibata R., Sakuragi J., Sakuragi S., Kawamura M., Adachi A. Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol. 1993 Mar;67(3):1663–1666. doi: 10.1128/jvi.67.3.1663-1666.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Sakai K., Ma X. Y., Gordienko I., Volsky D. J. Recombinational analysis of a natural noncytopathic human immunodeficiency virus type 1 (HIV-1) isolate: role of the vif gene in HIV-1 infection kinetics and cytopathicity. J Virol. 1991 Nov;65(11):5765–5773. doi: 10.1128/jvi.65.11.5765-5773.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Simm M., Shahabuddin M., Chao W., Allan J. S., Volsky D. J. Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol. 1995 Jul;69(7):4582–4586. doi: 10.1128/jvi.69.7.4582-4586.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Simon J. H., Malim M. H. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol. 1996 Aug;70(8):5297–5305. doi: 10.1128/jvi.70.8.5297-5305.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Smith A. J., Cho M. I., Hammarskjöld M. L., Rekosh D. Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles. J Virol. 1990 Jun;64(6):2743–2750. doi: 10.1128/jvi.64.6.2743-2750.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Sodroski J., Goh W. C., Rosen C., Tartar A., Portetelle D., Burny A., Haseltine W. Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science. 1986 Mar 28;231(4745):1549–1553. doi: 10.1126/science.3006244. [DOI] [PubMed] [Google Scholar]
  43. Sova P., Volsky D. J. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol. 1993 Oct;67(10):6322–6326. doi: 10.1128/jvi.67.10.6322-6326.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Sova P., van Ranst M., Gupta P., Balachandran R., Chao W., Itescu S., McKinley G., Volsky D. J. Conservation of an intact human immunodeficiency virus type 1 vif gene in vitro and in vivo. J Virol. 1995 Apr;69(4):2557–2564. doi: 10.1128/jvi.69.4.2557-2564.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Strebel K., Daugherty D., Clouse K., Cohen D., Folks T., Martin M. A. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature. 1987 Aug 20;328(6132):728–730. doi: 10.1038/328728a0. [DOI] [PubMed] [Google Scholar]
  46. Studier F. W., Rosenberg A. H., Dunn J. J., Dubendorff J. W. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 1990;185:60–89. doi: 10.1016/0076-6879(90)85008-c. [DOI] [PubMed] [Google Scholar]
  47. Tomaszek T. A., Jr, Magaard V. W., Bryan H. G., Moore M. L., Meek T. D. Chromophoric peptide substrates for the spectrophotometric assay of HIV-1 protease. Biochem Biophys Res Commun. 1990 Apr 16;168(1):274–280. doi: 10.1016/0006-291x(90)91704-v. [DOI] [PubMed] [Google Scholar]
  48. Tritch R. J., Cheng Y. E., Yin F. H., Erickson-Viitanen S. Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein. J Virol. 1991 Feb;65(2):922–930. doi: 10.1128/jvi.65.2.922-930.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Vieira J., Messing J. The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers. Gene. 1982 Oct;19(3):259–268. doi: 10.1016/0378-1119(82)90015-4. [DOI] [PubMed] [Google Scholar]
  50. Wang C. T., Barklis E. Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants. J Virol. 1993 Jul;67(7):4264–4273. doi: 10.1128/jvi.67.7.4264-4273.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Wills J. W., Craven R. C. Form, function, and use of retroviral gag proteins. AIDS. 1991 Jun;5(6):639–654. doi: 10.1097/00002030-199106000-00002. [DOI] [PubMed] [Google Scholar]
  52. Zybarth G., Carter C. Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing. J Virol. 1995 Jun;69(6):3878–3884. doi: 10.1128/jvi.69.6.3878-3884.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. von Schwedler U., Song J., Aiken C., Trono D. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol. 1993 Aug;67(8):4945–4955. doi: 10.1128/jvi.67.8.4945-4955.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES